SCHEDULE: Activist Investor Demands CEO Ouster at Valion Bio

3i, LP, a significant shareholder in Valion Bio, Inc., has formally demanded the immediate removal of CEO Michael Handley, citing sustained mismanagement and destruction of shareholder value.

Summary

• 3i, LP, along with associated entities Tumim Stone Capital, LLC and 3i Management LLC, collectively hold a 9.9% stake in Valion Bio, Inc.
• The filing is an amendment to a previous Schedule 13G, now filed as a Schedule 13D, indicating a shift in reporting requirements.
• 3i, LP has sent a letter to the Board of Directors demanding the immediate removal of CEO Michael Handley, citing mismanagement and destruction of shareholder value.
• The reporting persons have acquired their stake through various transactions including convertible notes, preferred stock, warrants, and a common stock purchase agreement.
• Tumim Stone Capital, LLC has an at-the-market offering facility with the company, subject to registration statement effectiveness.
• The reporting persons state their shares are held for investment purposes but reserve the right to engage in discussions and consider future actions regarding the company's management and strategy.
• The total outstanding shares of common stock are stated as 4,407,364 as of July 7, 2026, with additional shares issued to 3i, LP on July 19, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the activist investor's demand for CEO removal, indicating significant dissatisfaction with current management and potential for disruptive corporate action.

Positives

• 3i, LP expresses continued belief in Valion Bio's underlying potential in its science, people, and market position.
• The reporting persons are prepared to continue supporting the company toward its potential, indicating a desire for the company to succeed under new leadership.
• Tumim Stone Capital, LLC has an effective registration statement for resale of shares issued under the ELOC Purchase Agreement, facilitating liquidity for shares acquired through this facility.

Negatives

• A significant shareholder (3i, LP) has formally demanded the immediate removal of the CEO, Michael Handley.
• The demand cites 'sustained mismanagement' and 'dereliction of the Board's duty of care and duty of loyalty' by the Board for not acting against the CEO.
• The letter states that 'every additional day Mr. Handley remains at the helm compounds the damage' and that 'current leadership runs it into the ground'.
• The reporting persons explicitly state their confidence is not in Michael Handley and that there is 'no acceptable transition period, no further review, and no additional time to deliberate'.
• The reporting persons reserve all rights available to them as shareholders should the Board fail to act promptly.

Risks

• Potential for significant disruption and uncertainty due to the demand for CEO removal and potential board action.
• The ongoing conflict between a major shareholder and current management could negatively impact operational focus and employee morale.
• The reporting persons reserve the right to increase or decrease their position, which could lead to further market volatility.
• The effectiveness of the ELOC Purchase Agreement for Tumim Stone Capital, LLC is contingent on the effectiveness of registration statements, which could be delayed or face SEC review.

Future Outlook

The reporting persons have no current plans or proposals beyond holding their investment, but reserve the right to consider future actions regarding the Issuer's management, operations, and strategic plans. They have demanded the immediate removal of the CEO and the commencement of a search for a replacement.

Management Comments

• "The Board's continued inaction in the face of Mr. Handley's sustained mismanagement is not a passive failure - it is, in our view, a dereliction of the Board's duty of care and duty of loyalty to the Company's shareholders."
• "Directors are fiduciaries. That role does not permit deference to a chief executive whose leadership is actively destroying shareholder value."
• "Valion Bio has tremendous underlying potential - in its science, its people, and its market position - and 3i remains prepared to continue supporting the Company toward that potential."
• "It is precisely because we believe in what this Company can become that we cannot continue to stand by while current leadership runs it into the ground."
• "Accordingly, we demand that the Board immediately remove Michael Handley as Chief Executive Officer and commence, without delay, a search for permanent leadership capable of restoring shareholder confidence and executing on the Company's potential."
• "There is no acceptable transition period, no further review, and no additional time to deliberate."
• "3i expects - and, as a significant shareholder, is entitled to - immediate and decisive action."

Industry Context

StockSavvy.ai notes that activist investor actions, particularly those demanding CEO removal, are becoming more frequent in the biotechnology sector as investors seek to unlock perceived value or correct perceived mismanagement in companies with significant scientific potential but challenging operational execution.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased volatility and uncertainty due to activist action; potential for improved governance and value if new leadership is appointed.
• Employees: Risk of disruption and morale issues due to leadership uncertainty and potential strategic shifts.
• Management: CEO Michael Handley faces immediate demand for removal; other management may face scrutiny or changes depending on the Board's decision.

Next Steps

• The Board of Directors is expected to respond to the demand for CEO removal.
• A search for a new CEO may commence if the demand is met.
• The reporting persons may consider further actions regarding the Issuer's management and strategy.
• Tumim Stone Capital, LLC may continue to purchase shares under the ELOC Purchase Agreement if the registration statement remains effective.

Key Dates

Recommendation

The demand for CEO removal introduces significant uncertainty and potential for disruption, making a 'hold' recommendation appropriate. While the activist's belief in the company's potential is positive, the immediate focus is on the governance conflict. Investors should await clarity on the Board's response and any subsequent leadership changes before considering a more definitive stance.

Keywords

Valion Bio, Schedule 13D, Activist Investor, CEO Removal, Shareholder Demand, 3i, LP, Convertible Note, Preferred Stock